Table 1.
Patients’ characteristics
| Characteristic | ccTGA (N = 8) | D-TGA (M/S) (N = 9) | All patients (N = 17) |
|---|---|---|---|
| Gender (male), n (%) | 4 (50) | 5 (55.6) | 9 (52.9) |
| Age (SD, range) (y) | 46.6 (13.4, 18-65) | 42.4 (6.4, 30-51) | 44.4 (10.5, 18-65) |
| BSA (SD) (m2) | 1.64 (0.2) | 1.63 (0.2) | 1.63 (0.20) |
| Surgical repair, n (%) | |||
| Mustard operation | – | 5 (55.6) | – |
| Senning operation | – | 4 (44.4) | – |
| Complex anatomy, n (%) | |||
| Ventricular septal defect | 4 (50) | 3 (33.3) | 7 (41.2) |
| Pulmonary stenosis | 4 (50) | 5 (55.6) | 9 (52.9) |
| Tricuspid regurgitation, n (%) | |||
| Mild | 6 (75) | 6 (66.7) | 12 (70.6) |
| Moderate or severe | 2 (25) | 3 (33.3) | 5 (29.4) |
| Tricuspid valve replacement, n (%) | 2 (25) | 2 (22.2) | 4 (23.5) |
| Tricuspid valve replacement in CMR intervals, n (%) | 0 (0) | 2 (22.2) | 2 (22.2) |
| NYHA class, n (%) | |||
| Ⅰ | 5 (62.5) | 4 (44.4) | 9 (52.9) |
| Ⅱ | 3 (37.5) | 4 (44.4) | 7 (41.2) |
| Ⅲ/Ⅳ | 0 (0) | 1 (11.1) | 1 (5) |
| Pulmonary hypertension, n (%) | 0 (0) | 4 (44.4) | 4 (23.5) |
| Brain natriuretic peptide (pg/mL) | 53.3 (27.8) | 55.1 (39.1) | 54.2 (34.3) |
| ECG, n (%) | |||
| Sinus | 6 (75) | 9 (100) | 15 (88.2) |
| Supraventricular tachycardia | 2 (25) | 0 (0) | 2 (11.8) |
| QRS width (SD) (ms) | 123.4 (22.4) | 124.3 (28.7) | 122.2 (25.7) |
| Medications (at last CMR assessment), n (%) | |||
| β-Blocker | 5 (62.5) | 5 (55.6) | 10 (58.8) |
| SGLT2 inhibitor | 2 (25) | 1 (11.1) | 3 (17.6) |
| MRA | 4 (50) | 5 (55.6) | 9 (52.9) |
| Diuretics | 4 (50) | 5 (55.6) | 9 (52.9) |
BSA, body surface area; ccTGA, congenitally corrected transposition of the great arteries; CMR, cardiac magnetic resonance; D-TGA (M/S), dextro-transposition of the great arteries after Mustard/Senning operations; ECG, electrocardiogram; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SD, standard deviation; SGLT2, sodium-dependent glucose transporter 2 inhibitor.